
|Articles|April 24, 2004
Genentech enrolling patients for Lucentis clinical trial
Genentech, South San Francisco, CA, announced that the biotechnologycompany is enrolling patients into a Phase III clinical trial for its age-relatedmacular degeneration (AMD) drug Lucentis (ranibizumab, rhuFab V2).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Spotlight on women's health: Understanding thyroid eye disease
2
The Atrophy Advisor: An online tool to inform GA treatment decisions
3
Seeing the difference: Multimodal imaging for AMD and GA
4
Screening for Demodex blepharitis: Integrating best practices into routine eye care
5








































